Best Life Sciences Companies in Columbus, United States
The 77 best Life Sciences companies in Columbus, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Forge Biologics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Columbus
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Forge Biologics Developer of gene therapeutic solutions for treating multiple diseases | $330M | 45 mo ago | 118 | Jaysson Eicholtz Co-Founder | WordPress Block EditorWordPressApple iCloud Mail+25 | 27 patents Improving viral vector manufacturing for gene therapy: safer AAV producer cells, adenoviral helpers, optimized Kozak sequences. | — |
| 2 | Navidea Biopharmaceuticals Developer of immunodiagnostic agents and immunotherapeutics for cancer and inflammatory diseases | $111M | 63 mo ago | 14 | Michael Goldberg CEO | BootstrapApache HTTP ServerjQuery+7 | 153 patents Mannose‑decorated dextran nanocarriers for CD206‑targeted drug delivery to macrophages | — |
| 3 | Basking Biosciences Developer of therapeutics for ischemic stroke treatment | $90M | 28 mo ago | 4 | Rich Shea CEO | WordPressPleskMySQL+18 | — | 1 partnership · 1 award |
| 4 | Sollis Therapeutics Developer of non-opioid and non-steroids therapies for sciatica | $52M | 62 mo ago | 4 | — | — | — | — |
| 5 | Avation Developer of wearable device for at-home treatment of overactive bladder symptoms | $35M | 28 mo ago | 24 | Manish Vaishya Co-Founder & CTO | SanityNode.jsTailwind CSS+10 | — | — |
| 6 | Clarametyx Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections | $33M | 16 mo ago | 14 | — | — | — | — |
| 7 | Floshield Innovative laparoscopic vision system enhancing clarity and efficiency during surgical procedures | $26M | 127 mo ago | 3 | — | — | 7 patents Enhanced visualization technologies for surgical endoscopes and scopes | — |
| 8 | Deep Lens AI and cloud-based digital pathology platform | $17M | 86 mo ago | 39 | Dave Billiter Co-Founder & CEO | — | — | — |
| 9 | Cytonus Therapeutics Developer of adoptive cellular therapy for cancer treatment | $14M | 31 mo ago | 10 10 → 6 (-40%) | — | — | — | — |
| 10 | Cardiox Corporation Diagnostic devices for measuring the magnitude of Patent foramen ovale in a patient | $14M | 146 mo ago | 9 | — | — | 29 patents Non‑invasive cardiovascular monitoring and hepatic function assessment technologies | — |
| 11 | ParaGen Technologies Developer of tissue engineering technologies | $12M | 55 mo ago | 16 | Flavio Lobato Co-Founder | — | — | — |
| 12 | Invirsa Natural small molecule indicated for acute conjunctivitis of viral origin | $9M | 11 mo ago | 3 | — | — | 42 patents Ocular therapeutics using ADPR to modulate VEGF and improve visual acuity | — |
| 13 | PercuVision Visibility improving solutions for urologists | $9M | 97 mo ago | 15 | — | — | 14 patents Catheter-based optical/thermal sensing and therapeutic devices for internal healing and urology | — |
| 14 | Capsa Healthcare Provider of medication management system for healthcare providers and pharmacies | $8M | 199 mo ago | 291 | Andrew Sherrill CEO & President | WordPressMySQLSalesforce+46 | — | — |
| 15 | Signet Accel Uncensored adult entertainment: live sex cams, chatrooms, and performers | $8M | 105 mo ago | 28 | — | — | — | — |
| 16 | S4 Medical Developer of catheter ablation treatment for atrial fibrillation | $8M | 35 mo ago | 8 | Emile Daoud Co-Founder | — | 547 patents Patents concentrated in health & consumer products | — |
| 17 | Eikonoklastes Developer of tissue factor targeting therapeutics to treat cancer | $7M | 11 mo ago | 3 | Zhiwei Hu Co-Founder | — | — | — |
| 18 | Leadscope Chemoinformatics platform for chemical toxicity assessment. | $7M | 218 mo ago | 6 | Loftus Lucas President and CEO | — | — | — |
| 19 | MassMatrix Proteomics data analysis software | $3M | 14 mo ago | 3 | Hall Johnson Co-Founder & CEO | Cart FunctionalityWordPressMySQL+30 | — | 1 launch |
| 20 | Armatus Developer of precision gene therapies for rare diseases | $3M | 13 mo ago | 9 | Scott Harper Co-Founder | WordPressMySQLPHP+19 | — | — |
| 21 | Carmel Pharma Closed system drug transfer device | $3M | 246 mo ago | 32 | — | — | — | — |
| 22 | Myonexus Therapeutics Genetic medicine company engineering solutions for rare diseases | $2M | 102 mo ago | 4 | Michael Triplett Co-Founder & CEO | — | — | — |
| 23 | Clevex Disposable excision and closure devices | $2M | 195 mo ago | — | Gary Smith President & CEO | — | 12 patents Surgical wound closure clips and adhesive sutures; biopsy blades and punches. | — |
| 24 | TegoSens Developer of remote monitoring device for heart failures | $2M | 64 mo ago | 4 | Emre Ertin Co-Founder | — | 7 patents Precise chest placement devices for wearable physiological sensors (e.g., ECG/respiration). | — |
| 25 | Neurxstem Developer of a neural organoid platform | $2M | 73 mo ago | — | Rene Anand Founder & CEO | — | — | — |
| 26 | Vertebration Spinal implant systems | $2M | 199 mo ago | — | Henry Fabian Co-Founder & CEO | — | 6 patents Spinal surgical instruments and implant deployment systems for vertebral procedures | — |
| 27 | Columbus NanoWorks Provider of surface-functionalized, fluorescent nano-diamond materials | $2M | 97 mo ago | — | — | — | 8 patents Quantum diamond biosensing and engineered magnetic nanoparticle production for biomedical applications | — |
| 28 | Nanofiber Solutions 3D nanofiber scaffolds for regenerative medicine, veterinary, and cell culture | $2M | 83 mo ago | 8 | — | — | 118 patents Nanofiber biomedical scaffolds for tissue engineering, drug delivery, electroporation, and cultured meat | — |
| 29 | Myoptechs Developer of medical device for myopia correction | $1M | 21 mo ago | — | Paul Grimm Co-Founder & CEO | — | — | — |
| 30 | GenomeNext Genomic analysis platform for next gen sequencing | $1M | 112 mo ago | 5 | — | — | — | — |
| 31 | ZeoVation Supplier of antimicrobial and zeolite particle technology. | $780K | 15 mo ago | 4 | Bo Wang Co-Founder | — | 4 patents Zeolite-based antimicrobial agents for biofilm, virus, and fungal control | — |
| 32 | RenovoDerm Developer of nanofiber-based wound care devices | $775K | 25 mo ago | 4 | Jed Johnson Co-Founder and CTO | — | — | — |
| 33 | ProclaRx Developing bacterial film inhibitor drugs for infectious diseases | $512K | 111 mo ago | 3 | — | — | — | — |
| 34 | Hilo Nutrition Provider of pre-workout gummies | $503K | 86 mo ago | 4 | — | — | — | — |
| 35 | DIRAmed Non-invasive meters to measure key body ingredients | $375K | 180 mo ago | 4 | Robert Schlegel Chairman | — | 16 patents Calibration shutter assemblies for spectroscopic medical imaging devices | — |
| 36 | ExonanoRNA Developer of RNA nanoparticles for research and pre-clinical development | $295K | 45 mo ago | 9 | Fengmei Pi Co-Founder & CEO | Cloudflare Browser InsightsCloudflareHTTP/3 | — | — |
| 37 | Elastance Imaging Manufacturer of clinical imaging diagnostic devices | $225K | 44 mo ago | — | William Timmons CEO | — | — | — |
| 38 | BehaviorCloud Cloud based platform for clinical trial data management | $220K | 93 mo ago | — | Derek Edwards Co-founder and Investor | — | — | — |
| 39 | Core Quantum Technologies Developer of probe system to create the sharper image | $150K | 81 mo ago | 5 | Jessica Winter Founder & CSO | — | — | — |
| 40 | MatchTx Matching cancer patients to therapeutics using deep genetic signatures | $110K | 77 mo ago | — | Jeff Spitzner CEO | — | — | — |
| 41 | Rekovo Provider of a device for physical rehabilitation | $100K | 140 mo ago | 3 | Todd Whittington Co-Founder & CEO | — | — | — |
Top 12 Life Sciences companies in Columbus
#1
Series B · Columbus, Ohio · founded 2014 · 3 employees$9.3Mraised▾
Natural small molecule indicated for acute conjunctivitis of viral origin. The lead candidate, INV-102, is derived from a naturally occurring small molecule that modulates the activity of three parallel enzyme systems that are critical to innate immune response. NV-102 significantly reduces plaque formation caused by adenovirus. The candidate shows a strong anti-inflammatory response in acute conjunctivitis, without the side effects from other therapeutics like steroids.
- Jul 2025Series B$2.9M
- Nov 2023Series B$1000K
- Jun 2023Series B$7.7M
- Dec 2020Seed$40.2K
#2
Series B · Columbus, Ohio · founded 2019 · 3 employees$7.2Mraised▾
Developer of tissue factor targeting therapeutics to treat cancer. The company is developing tissue factor targeting therapies that target cell surface receptors for cancers, endometriosis, and other diseases. The company has developed an L-ICON3 platform to create immune therapies engineered with a ligand conjugated to an IgG3 Fc to enable it to bind to cancer cells and treat triple-negative breast cancer. The cells activate complement activation (CDC) and antibody-dependent cellular cytotoxicity (ADCC) to kill cancer cells.
- Jul 2025Series B$15.8M
- Jun 2024Series B$2.4M
- Nov 2023Series A$2M
- Jan 2022Series A$2.8M
#3
Series A · Columbus, Ohio · founded 2019 · 14 employees$33Mraised▾
Clarametyx Biosciences has developed biologic therapies and vaccines for biofilm-related bacterial infections affecting the respiratory tracts. The company has developed its lead product CMTX-001, an immune-enabling antibody therapy, to treat hospital-acquired pneumonia (preclinical development stage). It is also developing therapies for cystic fibrosis, sinusitis, and post-tympanostomy tube otorrhea.
- Jan 2025Series A—
- Jan 2024Series A$33M
- Apr 2022Grant (prize money)$3.9M
- Jan 2022Grant (prize money)$3.1M
#4
Funding Raised · Columbus, Ohio · founded 2015 · 3 employees$3.1Mraised▾
Proteomics data analysis software. The software offers features such as Mass Accuracy Sensitive Probabilistic Scoring Model, Automated Disulfide Linkage, and Chemical Cross-Linkage Searching using the company's proprietary XMapper algorithm, Post-translational modification search, Hierarchical MSn spectral database searching for peptides, and visualization tools.
- Apr 2025Grant (prize money)$316.8K
- Jul 2023Grant (prize money)$1.7M
- May 2019Grant (prize money)$1.1M
#5
Seed · Columbus, Ohio · founded 2020 · 9 employees$3Mraised▾
Developer of precision gene therapies for rare diseases. It offers AAV-based gene replacement therapy candidates which include ARM 101, ARM 102, ARM 201, and ARM 202 for neuromuscular disorders.
- May 2025Seed$3M
#6
Series C · Columbus, Ohio · founded 2019 · 4 employees$89.8Mraised▾
Developer of therapeutics for ischemic stroke treatment. It offers a drug candidate BB-031 which is an RNA aptamer that inhibits von Willebrand Factor and has demonstrated potent vessel recanalization. It also offers BB-025 a sequence-specific reversal oligonucleotide that neutralizes the pharmacologic effect of BB-031.
- Feb 2024Series C$55M
- Oct 2023Series C$55M
- Dec 2020Seed$5.4M
- Sep 2020Seed$1.9M
#7
Seed · Columbus, Ohio · founded 2016 · 4 employees$780Kraised▾
{}
- Mar 2025Grant (prize money)$1.2M
- Sep 2020Grant (prize money)$1M
- Jul 2019Seed$220K
- Feb 2019Grant (prize money)$250K
#8
Acquired · Columbus, Ohio · founded 2020 · 118 employees$330Mraised▾
Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.
- Sep 2022Series C$90M
- Jan 2022Conventional Debt$80M
- Apr 2021Series B$120M
- Jul 2020Series A$40M
#9
Series C · Columbus, Ohio · founded 1999 · 24 employees$34.9Mraised▾
Developer of wearable device for at-home treatment of overactive bladder symptoms. It offers Vivally that uses physiologic closed-loop controlled transcutaneous tibial nerve stimulation (PCL TTNS) with continuous EMG sensing, worn on the ankle.
#10
Seed · Columbus, Ohio · founded 2022$1.3Mraised▾
Developer of medical device for myopia correction. It offers soft contact lens based on Faceted Optical System designed to slow the progression of myopia and reducing the short-and long-term vision implications of chronic and progressive myopia.
- Aug 2024Seed$1.3M
#11
Series A · Columbus, Ohio · founded 2018 · 10 employees$14.4Mraised▾
Developer of adoptive cellular therapy for cancer treatment. The company is using its proprietary platform for developing cargocytes which are engineered enucleated cells used for targeting specific cancer cells. They are specifically designed to locate and activate the host’s immune system to attack cancer cells. The company's lead product candidate GM1215 against pancreatic cancer is in Phase 1 clinical trials.
- Oct 2023Series A$11.7M
- Sep 2023Grant (prize money)$2M
- Sep 2021Grant (prize money)$297.6K
- Aug 2021Grant (prize money)$325K
#12
Public · Columbus, Ohio · founded 1983 · 14 employees$111.4Mraised▾
Developer of immunodiagnostic agents and immunotherapeutics for cancer and inflammatory diseases. It focuses on developing innovative agents and immunotherapeutics that can make a difference for individuals, families, physicians and care givers touched by devastating conditions like cancer, autoimmune, infectious and inflammatory diseases. It aspires to provide innovative immunodiagnostic agents and therapies to improve patient care for serious diseases.
- Mar 2021Post IPO$5M
- Dec 2019Post IPO$1.9M
- Sep 2019Grant (prize money)$175.3K
- Mar 2019Post IPO$50K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.